Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2021 / Article

Research Article | Open Access

Volume 2021 |Article ID 6630795 | https://doi.org/10.1155/2021/6630795

Zhen-Zhong Zang, Li-Mei Chen, Yuan Liu, Yong-Mei Guan, Qing Du, Pan Xu, Qian Shen, Ming Yang, Hong-Ning Liu, Zheng-Gen Liao, "Uncovering the Protective Mechanism of the Volatile Oil of Acorus tatarinowii against Acute Myocardial Ischemia Injury Using Network Pharmacology and Experimental Validation", Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 6630795, 16 pages, 2021. https://doi.org/10.1155/2021/6630795

Uncovering the Protective Mechanism of the Volatile Oil of Acorus tatarinowii against Acute Myocardial Ischemia Injury Using Network Pharmacology and Experimental Validation

Academic Editor: Abraham Wall Medrano
Received15 Nov 2020
Revised13 Apr 2021
Accepted21 Apr 2021
Published22 Jun 2021

Abstract

Acorus tatarinowii is a traditional aromatic resuscitation drug that can be clinically used to prevent cardiovascular diseases. The volatile oil of Acorus tatarinowii (VOA) possesses important medicinal properties, including protection against acute myocardial ischemia (MI) injury. However, the pharmacodynamic material basis and molecular mechanisms underlying this protective effect remain unclear. Using network pharmacology and animal experiments, we studied the mechanisms and pathways implicated in the activity of VOA against acute MI injury. First, VOA was extracted from three batches of Acorus tatarinowii using steam distillation, and then, its chemical composition was determined by GC-MS. Next, the components-targets and protein-protein interaction networks were constructed using systematic network pharmacology. Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were also conducted in order to predict the possible pharmacodynamic mechanisms. Furthermore, animal experiments including ELISAs, histological examinations, and Western blots were performed in order to validate the pharmacological effects of VOA. In total, 33 chemical components were identified in VOA, and ß-asarone was found to be the most abundant component. Based on network pharmacology analysis, the therapeutic effects of VOA against myocardial ischemia might be mediated by signaling pathways involving COX-2, PPAR-α, VEGF, and cAMP. Overall, the obtained results indicate that VOA alleviates the pathological manifestations of isoproterenol-hydrochloride-induced myocardial ischemia in rats, including the decreased SOD (superoxide dismutase) content and increased LDH (lactic dehydrogenase) content. Moreover, the anti-MI effect of VOA might be attributed to the downregulation of the COX-2 protein that inhibits apoptosis, the upregulation of the PPAR-α protein that regulates energy metabolism, and the activation of VEGF and cAMP signaling pathways.

1. Introduction

Cardiovascular diseases are the leading cause of morbidity and mortality in the world. In China, the prevalence of cardiovascular diseases is increasing year after year. Myocardial ischemia (MI), one of the main pathogenic mechanisms of cardiovascular diseases [1, 2], is a pathological state characterized by reduced blood perfusion and oxygen supply to the heart. As a metabolic disease, this state leads to abnormal myocardial energy metabolism and disrupts normal heart function. Patients suffering from mild MI have angina pectoris and arrhythmia; whereas, those suffering from the severe disease exhibit myocardial infarction, which eventually leads to death [3]. Acute ischemia, hypoxia, and metabolic disorders in the myocardial tissues are caused by severe spasms, sudden coronary artery obstruction, low blood pressure, reduced aortic blood supply, change in blood viscosity, valvular disease, and myocardial disease [4, 5].

The genus Acorus belongs to the Acoraceae family that is widely distributed in temperate and subtropical regions, and it includes Acorus tatarinowii (shi chang pu), Acorus calamus L (shui chang pu), Acorus gramineus Aiton (jin xian pu), and Acorus macrospadiceus F. N. Wei (shannai chang pu) species [6, 7]. Although Acorus tatarinowii is similar to Acorus calamus L, the former is smaller in terms of morphology, and its leaves lack a midrib. Moreover, Acorus tatarinowii is more frequently used for medicinal purposes [7], and it is recognized as a traditional aromatic resuscitation medicine that eliminates phlegm, refreshes the mind, nourishes intelligence, dispels dampness, and stimulates appetite [8, 9]. The volatile oil of Acorus tatarinowii (VOA) is one of the ingredients responsible for its medicinal properties. According to previous pharmacological studies, VOA can be used to treat or prevent cardiovascular diseases [1014]. The chemical composition of VOA is complex, and so far, more than 60 components have been identified [15], including phenylpropanoids (α-asarone, ß-asarone, methyl eugenol, isomethyl eugenol, and elemene), monoterpenoids (borneol, camphor, α-pinene, ß-pinene, and kenene), and sesquiterpenoids (β-elemene, ß-syringene, and colicone) [16]. Among these various components, -asarone and ß-asarone are primarily responsible for the cardiovascular system-protection activity of VOA [1721]. In particular, α-asarone and ß-asarone reduce the endothelin (ET) level and increase the NO content. Moreover, they decrease plasma viscosity and necrosis in rats with myocardial ischemia, improve the blood flow in rats with hyperviscosity, and reduce blood lipid levels in atherosclerotic rats, which proves that they can protect the cardiovascular system [14,22].

Although VOA protects against acute MI injury, its pharmacodynamic material basis and the underlying molecular mechanisms have not yet been elucidated. In this study, we explore these mechanisms using network pharmacology and animal experiments. Network pharmacology is a tool used to systematically study multicomponent drug mechanisms by analyzing the relationships between drugs, compounds, drug targets, diseases, and pathways [23, 24]. Considering that traditional Chinese medicine (TCM) involves many small compounds that may simultaneously, transiently, or weakly bind with multiple target proteins [25, 26], it is important to analyze the effects of herbal treatments on various diseases using a holistic approach. The holistic perspective of TCM is consistent with the key idea of network pharmacology [27], wherein the potential mechanisms of active TCM components are systematically elaborated by constructing molecular networks [28, 29].

2. Materials and Methods

2.1. Materials

Acorus tatarinowii, propranolol hydrochloride tablets, and isoproterenol hydrochloride injection were purchased from Hebei Jinye Pharmaceutical Co. Ltd. (Hebei, China), Jiangsu Yabang Epson Pharmaceutical Co. Ltd. (Jiangsu, China), and Shanghai Wellhope Pharmaceutical Co. Ltd. (Shanghai, China), respectively. SOD, LDH, COX-2, and PPARα ELISA kits were obtained from Jiangsu Meimian Industry Co., Ltd. (Jiangsu, China), while COX-2 antibodies and GADPH antibodies were purchased from Abcam (Cambridge, England). PPAR-α antibodies were bought from Beijing Boaosen Biotechnology Co. Ltd. (Beijing, China).

2.2. Extraction of the Volatile Oil

Acorus tatarinowii was verified by Associate Professor Kezhong Deng and deposited in the key laboratory of modern preparation at Jiangxi University of Traditional Chinese Medicine. Three hundred grams of the rhizome of Acorus tatarinowii (190127c103, Hebei, China) were weighed and placed in a round bottom flask, followed by soaking in water for 30 min. The volatile oil in the rhizome was extracted by steam distillation for 9 h, and then, it was dehydrated with anhydrous sodium sulfate. After measuring the volume of the dehydrated oil, the sample was transferred to a brown bottle and stored at 4°C.

2.3. Quality Control

Fingerprint technology is often used to control the quality of TCM plants. Herein, we extracted the volatile oils of three batches of Acorus tatarinowii (S1: 170801c103, S2: 181001c103, and S3: 190127c103) and established the fingerprint of VOA for quality control.

2.4. Composition of VOA

To determine the chemical composition of VOA, 10 mg of the VOA was added to methanol (181128, Guangzhou, China) in a 25 mL volumetric flask. After adjusting the volume and homogenizing the mixture, 25 μL of the resulting solution was diluted with methanol in a 10 mL volumetric flask. The obtained test solution was analyzed by gas chromatography/mass spectrometry using a DB-624 elastic quartz capillary column (30 m × 320 μm × 1.8 μm) (Agilent, USA) and an EI ion source. Chromatographic separation was achieved using a 1 mL/min flow of helium gas, and the injection port temperature and pressure were set at 260°C and 55.3 kPa, respectively. The split ratio of the injected sample (1 μL) was maintained at 20 : 1. The temperature of the column was programmed as follows: conditioning at 50°C for 3 min, run at the initial temperature of 70°C, and increase temperature to 120°C at the rate of 10°C/min (held for 0 min) and then to 265°C at the rate of 5°C/min (held for 3 min). The temperature of the ion source was set at 230°C, whereas that of the quadrupole was 150°C. The electron energy, multiplier voltage, solvent delay time, and mass range were 70 eV, 2.46 kV, 3 min, and 30–650, respectively.

2.5. Screening of Targets Related to the Chemical Constituents and MI

The chemical structures and SMILES strings of the identified VOA components were taken from PubChem (https://pubchem.ncbi.nlm.nih.gov/) and TCMSP (http://lsp.nwu.edu.cn/tcmsp.php/). The SMILES strings of the compounds were entered into the SwissTargetPrediction (http://www.swisstargetprediction.ch/) and STITCH (http://stitch.embl.de/) servers to determine the potential targets. After listing all targets, duplicates were removed, and the final potential targets of the VOA were obtained. The targets related to myocardial ischemia were obtained from the OMIM (https://www.omim.org/) and DisGeNET (http://www.disgenet.org/) databases using the phrase “myocardial ischemia” as search keyword. After listing all targets, duplicates were removed, and the final list of targets was obtained.

2.6. Construction of the Components-Targets Network and Protein-Protein Interaction (PPI) Network

First, the Venny 2.1.0 online software (https://bioinfogp.cnb.csic.es/tools/venny/index.html) was used to identify the overlapping targets amongst the lists of targets related to VOA components and myocardial ischemia disease. Then, a complex network was built between the components and overlapping targets. Protein-protein interaction (PPI) data were obtained from the STRING 11.0 database (https://string-db.org/). The overlapping targets were searched using the “multiple proteins” option and “Homo sapiens” organism, and the data were imported into Cytoscape 3.7.1 to build the PPI network.

2.7. Construction of the Organs-Targets Network

The BioGPS (http://biogps.org/#goto=welcome) database was used to determine the distribution of different targets in tissues or organs. The top ten tissues or organs were screened with gene expression, and the screening results were imported into Cytoscape 3.7.1 to build the overlapping targets-tissues/organs distribution network.

2.8. GO Function and KEGG Pathway Enrichment

The ClusterProfiler software package in the R-Studio platform was used to perform the GO function and KEGG pathway enrichment analyses of the coacting targets. In order to find the GO functions and KEGG pathways that are significantly enriched in the overlapping targets, the significance level was set to < 0.05.

2.9. Molecular Docking

Through molecular docking of chemical components and targets, the reliability of prediction results of potential targets can be further verified. The Discovery Studio 4.5 Client software was used to conduct molecular docking of chemical components of VOA and targets, and the docking score of the molecular docking results was analyzed to evaluate the degree of binding between the chemical components of VOA. The positive drug propranolol hydrochloride was also analyzed for molecular docking with targets.

2.10. Experimental Validation
2.10.1. Animals

Specific pathogen free (SPF) grade male Kunming mice, weighing 20 ± 2 g, were provided by the Experimental Animal Science and Technology Center of Jiangxi University of Traditional Chinese Medicine (license number: SCXK (Gan) 2018–0003). All mice were kept at temperatures of 18–25°C and provided with water. The animal procedures performed herein were all approved by the Ethics Committee of the Experimental Animal Science and Technology Center (NO. JZLLSC2019-0139).

2.10.2. Induction of Acute MI Injury

The mice were randomly divided into six groups, with eight mice in each group: (1) control group, (2) acute MI injury model group (model group), (3) low dose of the VOA group (55 mg kg−1 d−1), (4) medium dose of the VOA group (110 mg kg−1 d−1), (5) high dose of the VOA group (220 mg kg−1 d−1), and (6) propranolol group (E180913, Jiangsu, China) (48 mg kg−1 d−1). The mice in groups (3)–(6) were administered with VOA by gavage once a day for 17 consecutive days. Meanwhile, the mice in groups (1) and (2) were given equivalent volumes of normal saline (190104, Guangzhou, China). The animal model of acute MI injury was established using previously reported methods [30, 31]. In brief, all mice, except for control group mice, were intraperitoneally injected with isoproterenol hydrochloride (190104, Shanghai, China) (10 mg kg−1 d−1) on day 15 for three consecutive days. The injections were administered one hour after intragastric VOA ingestion. Instead of isoproterenol hydrochloride, the mice in the control group were intraperitoneally injected with the same volume of normal saline.

2.10.3. Sample Collection

On the last day of the experiment, the mice were sacrificed under pentobarbital sodium anesthesia, and blood samples were collected and centrifuged at 3500 r/min for 15 min. The supernatants were stored at −80°C for further analysis. The heart was quickly dissected, and some heart tissues were put in 10% paraformaldehyde solution for histopathological examination. The remaining tissues were stored in a refrigerator at −80°C.

2.10.4. Determination of SOD and LDH Concentrations in Serum and Histological Examination

The biochemical indexes of serum SOD and LDH (1911M, MEIMIAN, Jiangsu, China) were determined as the instructions. The myocardial tissues were fixed with 10% formaldehyde solution for 48 h, embedded in paraffin, cut into 4 mm sections, and stained with hematoxylin and eosin. The histological images were studied under light microscopy (200×).

2.10.5. ELISA Measurements of COX-2 and PPAR-α Levels

The COX-2 and PPAR-α levels in the myocardium were measured using the COX-2 mouse ELISA kit (MM-0356M1, Jiangsu, China) and PPAR-α mouse ELISA kit (MM-0249M1, Jiangsu, China), respectively.

2.10.6. Western Blot Analysis

To determine the COX-2 and PPAR-α protein contents in the myocardial tissues of mice, a specific amount of the tissues was placed in a tissue homogenizer for full homogenization. Afterward, RIPA (Solaibao, Beijing, China) was added to completely lyse the tissues. Subsequently, the lysed samples were centrifuged at 12000 g and 4°C for 15 min, and then, the supernatants were collected for protein quantification using the BCA protein analysis kit (PICPI23223, Thermo, Waltham, USA). The proteins were separated on a 10% resolution SDS-PAGE gel (S1010, Solaibao, Beijing, China) and then transferred to a nitrocellulose membrane (HATF00010, Millipore, Waltham, USA). In turn, the membrane was blocked with 5% skimmed milk and incubated overnight with antibodies on a 4°C cradle. The antibodies used for Western blotting include anti-COX-2 (1 : 1000, ab15191, Abcam, Cambridge, England), anti-PPAR-α (1 : 800, Bs23398 R, Bioss, Beijing, China), and anti-GAPDH (1 : 2500, ab9485, Abcam, Cambridge, England) antibodies. Afterward, the membrane was incubated with HRP-labeled secondary antibodies (1 : 1000, A0208, Beyotime, China) at 37°C for 1 h. As per the required dosage, the ECL (WBKLS0100, Millipore, USA) luminescent solutions A and B were mixed evenly and added to the front of the membrane. The membrane was kept in the dark for 5 min, and then, the developer was poured out and carefully absorbed with paper. Finally, the membrane was covered with a layer of flat transparent paper and scanned using the imaging system (Tanon-5200, Tanon, China).

2.11. Statistical Methods

The data were statistically analyzed using the SPSS 17.0 software (Armonk International Business machines, New York, USA), and they are expressed as mean ± standard deviation (SD). Student’s t-test was used to compare different groups, and -values < 0.05 were considered to be statistically significant.

3. Results

3.1. Fingerprint Analysis of VOA

The GC-MS data of three VOA batches were imported into the Chinese medicine chromatographic fingerprint similarity evaluation system version A (2004) for similarity evaluation, and the S1 chromatogram was used as a reference spectrum. After multipoint calibration and automatic matching, the control fingerprint was acquired (Figure 1(a)). Based on the obtained results, the fingerprints of all three VOA batches are similar, and they have a common pattern.

3.2. Identification of VOA Constituents

The total ion flow chromatogram of VOA is shown in Figure 1(b). In total, 33 compounds were identified in VOA using GC-MS analysis (Table 1), with ß-asarone, α-asarone, benzene, 1,2,3-trimethoxy-5-(2-propenyl), methyl isoeugenol, and estragole accounting for 93.7% of the total composition.


NumberChemical compositionStructureMolecular formulaRelative percentage content

VOA1α-PineneC10H180.12
VOA2CampheneC10H160.29
VOA3β-PineneC10H180.11
VOA4o-CymeneC10H140.06
VOA5D-LimoneneC10H160.07
VOA6γ-TerpineneC10H160.05
VOA7CamphorC10H16O0.25
VOA8endo-BorneolC10H18O0.32
VOA9EstragoleC10H12O3.50
VOA10LongicycleneC15H240.19
VOA11CaryophylleneC15H240.24
VOA12γ-MuuroleneC15H240.40
VOA131H-Cyclopropa[a]naphthalene, 1a,2,3,5,6,7,7a,7b-octahydro-1,1,7,7a-tetramethyl-, [1aR-(1a.alpha.,7.alpha.,7a.alpha.,7b.alpha.)]-C15H240.11
VOA14Methyl isoeugenolC11H14O22.95
VOA151,3,5-Cycloheptatriene, 2,4-diethyl-7,7-dimethyl-0.39
VOA16Cyclohexyl-2,4-dimethylbenzene ketoneC15H20O0.15
VOA17α-GurjuneneC15H240.16
VOA18ShyobunoneC15H24O0.80
VOA191,6,10-Dodecatrien-3-ol, 3,7,11-trimethyl-C15H26O0.22
VOA20Benzene, 1,2,3-trimethoxy-5-(2-propenyl)-C15H24O4.84
VOA21HexadecaneC16H340.08
VOA22TumeroneC15H22O0.23
VOA23β-AsaroneC12H16O371.31
VOA24Cyclohexanone, 6-furfurylidene-2,2,3-trimethyl-0.25
VOA25Naphthalene, 1,2,3,5,6,7,8,8a-octahydro-1,8a-dimethyl-7-(1-methylethenyl)-, [1R-(1.alpha.,7.beta.,8a.alpha.)]-C15H240.33
VOA26Spiro[4.5]dec-6-en-8-one, 1,7-dimethyl-4-(1-methylethyl)-C15H24O0.45
VOA27α-AsaroneC12H16O37.26
VOA282H-Cyclopropa[a]naphthalen-2-one, 1,1a,4,5,6,7,7a,7b-octahydro-1,1,7,7a-tetramethyl-, (1a.alpha.,7.alpha.,7a.alpha.,7b.alpha.)-C15H22O2.45
VOA29Cyclolongifolene oxide, dehydro-C15H22O0.29
VOA302,4,6-Octatriene, 2,6-dimethyl-C10H161.39
VOA31Bicyclo[3.1.1]hept-3-en-2-one, 4,6,6-trimethyl-, (1S)-C10H14O0.22
VOA32IsocalamendiolC15H26O20.38
VOA335(1H)-Azulenone, 2,4,6,7,8,8a-hexahydro-3,8-dimethyl-4-(1-methylethylidene)-, (8S-cis)-C15H22O0.14

3.3. Targets Related to the Chemical Constituents and to MI

All targets retrieved from SwissTargetPrediction and STITCH databases were integrated, and the duplicates were removed. Overall, 589 (Supplementary Table S1) and 600 (Supplementary Table S2) targets related to the 33 VOA components and to the MI disease were obtained. Note that the disease targets were obtained through OMIM and DIGENET databases.

3.4. The Components-Targets Network

Figure 2(a) shows the 589 target symbols of the drug and the 600 gene symbols of the disease, 55 overlaps. These overlapping targets may be critical for VOA-mediated MI treatment. Supplementary Table S3 provides details regarding the 55 overlapping targets.

To assess how VOA may act against myocardial ischemia, the Cytoscape 3.7.1 software was used to build a “components-targets” network, as shown in Figure 2(b). The 33 blue nodes represent the VOA components, and the 55 green nodes represent the overlapping targets. The components-targets network analysis showed that the targets were highly correlated with multiple chemical components. For instance, ESR1 was associated with 16 components, PPAR-α with 12, and P2RX7 with 10. The key enzyme in prostaglandin biosynthesis, PTGS (also known as cyclooxygenase (COX)), was also correlated with 9 components. Therefore, inducible COX-2 was associated with nine components. Moreover, 24 chemical components were related to multiple targets. For example, α-asarone, ß-asarone, and artemisinol were associated with 19, 18, and 12 targets, respectively, and elemene, neroli, and methyl isoeugenol were all associated with 13 targets. It should be noted that the targets showing strong correlation with chemical components may play a significant role in the anti-MI activity of VOA. Detailed information regarding the chemical components and targets is given in Supplementary Tables S4 and S5.

3.5. PPI Network

As shown in Figure 3, the network graph comprises 55 nodes and 266 edges. In general, large degrees of freedom indicate high action intensity of the potential target. When the node color changes from dark pink to yellow, the degree value becomes small. The edges represent correlations between the overlapping targets. The greater the binding degree between the targets, the larger the binding score, and the more coarse the edge. Considering that the connecting edges of MAPK3 with STAT3, TNF with NFKBIA, STAT3 with JAK2, Ll6ST, and HIF1A, PTGS2 with STAT3, and CASP3 with PARP1 and MAPK14 are thicker than other edges, these targets showed greater degree of binding. Moreover, the MAPK3, TNF, STAT3, PTGS2, and CASP3 targets may play an important role in the anti-MI activity of VOA. Based on network analysis, the average local clustering coefficient was 0.623, and the average node degree was 9.67.

3.6. Construction of the Organs-Targets Network

In Figure 4, blue color represents the potential targets of VOA, whereas red color represents the tissues/organs in which these targets were distributed. The edges correspond to relationships between the targets and tissues/organs. Overall, 22 targets were distributed in the heart, and 22 genes were highly expressed in the cardiac myocytes. Moreover, many targets were distributed in the blood, liver, and retina. The genes of antigens CD33, CD14, CD56, and CD34 were also present.

3.7. GO and KEGG Analyses

GO and KEGG analyses were used to assess the biological characteristics of the potential VOA targets. The results reveal that the top predictors in biological processes (BP) include blood circulation, circulatory system processes, responses to molecules of bacterial origin and lipopolysaccharides, positive regulation of small-molecule metabolism and cytokine production, and blood circulation regulation. Therefore, VOA might play a role in the treatment of myocardial ischemia by improving these biological processes (Figure 5(a)). The biological processes related to PTGS2 and PPAR-α targets were blood circulation, circulatory system processes, and positive regulation of small-molecule metabolism. Hypothetically, these processes might play an important role in the treatment of myocardial ischemia by VOA. In terms of cellular components (CC), the top predictors were membrane raft, membrane microdomain, membrane region, membrane invagination, membrane raft plasma, ion channel complex, and transmembrane transporter complex (Figure 5(b)). The targets of PTGS2, TNF, NOS3, JAK2, HMOX1, and MAPK3 were related to membrane raft, membrane microdomain, and membrane region. Based on KEGG pathway enrichment analysis, the overlapping targets identified herein are implicated in 118 pathways that are mainly related to the metabolism, inflammation, immune function, and endocrine system. The top 20 KEGG pathways include AGE-RAGE (pathway involved in diabetic complications), sphingolipid, VEGF, prolactin, and cAMP signaling pathways. Supplementary Table S6 provides further details regarding these pathways. Figure 6 shows the pathway diagrams of VEGF and cAMP signaling generated in R Studio.

3.8. Molecular Docking

The top 5 targets with degree values in the “components-targets” network were selected for molecular docking verification. The 33 chemical components of the VOA and ESR1, PPAR-α, P2RX7, PTGS2, and EPHX2 were import into Discovery Studio 4.5 client for molecular docking. It is generally believed that docking score value greater than 100.0 indicates a strong binding activity between the molecule and the target, a value greater than 80.0 indicates a good binding activity, and a value above 60.0 indicates a certain binding activity between the molecule and the target. Table 2 provides that 28 chemical components in the VOA had good binding activity with important targets, and the docking of the positive drug propranolol hydrochloride with the target had a high score, which further explained the importance of ESR1, PPAR-α, P2RX7, PTGS2, and EPHX2.


TargetsPDB IDChemical compositionDocking score

ESR16PETVOA164.5085
P2RX75U2HVOA162.8344
PTGS25KIRVOA163.5080
ESR16PETVOA267.2673
P2RX75U2HVOA260.5152
PTGS25KIRVOA262.7291
ESR16PETVOA364.0894
P2RX75U2HVOA362.1425
PTGS25KIRVOA364.5139
ESR16PETVOA467.2681
PPAR-α3FEIVOA468.7501
P2RX75U2HVOA466.2316
PTGS25KIRVOA462.2260
EPHX23ANSVOA462.6863
ESR16PETVOA566.2105
PPAR-α3FEIVOA565.4939
P2RX75U2HVOA567.7889
PTGS25KIRVOA564.5092
EPHX23ANSVOA565.3003
ESR16PETVOA665.2575
PPAR-α3FEIVOA667.6596
P2RX75U2HVOA666.9050
PTGS25KIRVOA663.6252
EPHX23ANSVOA665.4785
ESR16PETVOA760.2374
PTGS25KIRVOA764.371
EPHX23ANSVOA761.3399
ESR16PETVOA867.4526
PTGS25KIRVOA864.3934
EPHX23ANSVOA861.9769
ESR16PETVOA968.2695
PPAR-α3FEIVOA971.5129
P2RX75U2HVOA972.5833
PTGS25KIRVOA971.6689
EPHX23ANSVOA971.4170
ESR16PETVOA1178.1423
PPAR-α3FEIVOA1166.9132
PTGS25KIRVOA1177.6608
EPHX23ANSVOA1170.2722
ESR16PETVOA1280.9465
PPAR-α3FEIVOA1274.2676
P2RX75U2HVOA1290.9012
PTGS25KIRVOA1277.8928
EPHX23ANSVOA1277.0346
ESR16PETVOA1578.0546
PPAR-α3FEIVOA1576.7342
P2RX75U2HVOA1583.8674
PTGS25KIRVOA1579.1801
EPHX23ANSVOA1574.6761
ESR16PETVOA1685.9312
PPAR-α3FEIVOA1683.2731
P2RX75U2HVOA1662.2699
PTGS25KIRVOA1692.4880
EPHX23ANSVOA1689.1537
ESR16PETVOA1883.9547
PPAR-α3FEIVOA1865.3407
PTGS25KIRVOA1885.8182
EPHX23ANSVOA1887.7297
ESR16PETVOA2096.4940
PPAR-α3FEIVOA2086.9967
P2RX75U2HVOA2097.3168
PTGS25KIRVOA20104.678
EPHX23ANSVOA2093.5532
ESR16PETVOA2167.9247
PPAR-α3FEIVOA2165.9274
PTGS25KIRVOA2166.2899
EPHX23ANSVOA2167.4975
ESR16PETVOA2269.3249
PPAR-α3FEIVOA2273.3223
P2RX75U2HVOA2265.2278
PTGS25KIRVOA2270.7295
EPHX23ANSVOA2274.0924
ESR16PETVOA2396.9734
PPAR-α3FEIVOA2399.8045
P2RX75U2HVOA2387.1190
PTGS25KIRVOA23102.692
EPHX23ANSVOA2388.7468
ESR16PETVOA2574.0667
PPAR-α3FEIVOA2564.8149
PTGS25KIRVOA2583.2913
EPHX23ANSVOA2577.1942
ESR16PETVOA2662.8586
PTGS25KIRVOA2690.0276
EPHX23ANSVOA2690.5615
ESR16PETVOA2784.2810
PPAR-α3FEIVOA2792.7826
P2RX75U2HVOA2781.9188
PTGS25KIRVOA27101.013
EPHX23ANSVOA2783.5758
PTGS25KIRVOA2981.0304
EPHX23ANSVOA2981.9996
ESR16PETVOA3065.5115
PPAR-α3FEIVOA3062.0720
P2RX75U2HVOA3066.2747
PTGS25KIRVOA3067.1910
EPHX23ANSVOA3063.4045
ESR16PETVOA3162.1971
P2RX75U2HVOA3164.2998
EPHX23ANSVOA3166.0117
PPAR-α3FEIVOA3261.9083
PTGS25KIRVOA3284.2783
EPHX23ANSVOA3280.7550
ESR16PETPropranolol95.8670
PPAR-α3FEIPropranolol98.2171
P2RX75U2HPropranolol90.1426
PTGS25KIRPropranolol112.0720
EPHX23ANSPropranolol107.5180

3.9. Experimental Validation
3.9.1. Serum Levels of SOD and LDH

Compared to the control group mice, the SOD level in the model group mice is significantly reduced (< 0.01), while the LDH level was significantly increased (< 0.01). This indicated that intraperitoneal injection of isoproterenol hydrochloride (10 mg kg−1 d−1) damages the hearts of mice, resulting in a successful MI model. Moreover, the medium dose of VOA, high dose of VOA, and propranolol groups exhibit significantly increased SOD levels (< 0.01) and significantly reduced LDH levels (< 0.01) compared to the control group. However, the SOD and LDH levels in low dose of VOA were comparable to those determined for the model group (> 0.05) (Figures 7(a) and 7(b)).

3.9.2. ELISA

The concentrations of COX-2 in the myocardium of the model group mice were significantly greater than that in the control group mice ( < 0.01). The concentrations of PPAR-α in the myocardium of the model group mice were significantly lower than that in the control group mice (< 0.01). Compared to the model group, the concentration of COX-2 in the medium dose of VOA, high dose of VOA, and propranolol groups were appreciably reduced (< 0.01), whereas that of PPAR-α was increased ( < 0.05). Similarly, treatment with low dose of VOA reduced the concentration of COX-2 ( < 0.05) in the myocardium and increased the concentration of PPAR-α ( > 0.05). Overall, these results indicated that VOA alleviates MI injury in mice (Figures 7(c) and 7(d)).

3.9.3. Histological Examination

The histological examination of myocardial fibers collected from the model group mice showed that these fibers were arranged in a disordered manner and that the myocardial tissues exhibit breaks, inflammatory cell infiltration, degeneration, and necrosis. However, VOA and propranolol hydrochloride treatments can improve the degree of myocardial injury in mice suffering from isoproterenol-hydrochloride-induced acute myocardial ischemia (Figure 8).

3.9.4. Western Blot Analysis

Compared to the control group, the expression of the COX-2 protein in the model group was significantly increased ( < 0.01), whereas that of the PPAR-α protein is significantly reduced ( < 0.01). However, treatment with low, medium, or high dose of VOA decreased the expression of COX-2 ( < 0.05,  < 0.01) and increased that of PPAR-α ( < 0.05,  < 0.01). Overall, the results indicated that VOA can improve acute MI injury in mice and that its effect was dose-dependent (Figure 9).

4. Discussion

In addition to the phenylpropanoid main active components, the volatile oil of Acorus tatarinowii (VOA) contains monoterpenes, sesquiterpenes, aliphatic aldehydes, and ketones [32]. In this study, we show that of all the components in VOA, ß-asarone, α-asarone, elemene, nerol, and methyl isoeugenol have the most targets. Except for neroli, which is a sesquiterpenoid, these compounds belong to the phenylpropanoid family. In general, phenylpropanoid compounds are known to protect the cardiovascular system by causing vasorelaxation and antiplatelet aggregation and by lowering the blood lipid level and the blood pressure. Moreover, they protect against ischemia/reperfusion injury and myocardial hypertrophy [33]. ß-Asarone has a variety of pharmacological effects, including myocardial cell protection [34, 35], anti-inflammation [36], vascular endothelial cell protection [37], antiplatelet aggregation and adhesion [38], and antiischemia [39]. Similarly, α-asarone exhibits antithrombosis, antiplatelet aggregation, and antihyperlipidemia activities, among others. As for neroli, it has antioxidation, anti-inflammatory, antibiofilm, skin penetration, antiulcer, antiworm, and anticancer effects [40]. By resisting the influence of reactive oxygen species [4143], neroli protects the cells from the oxidative damage induced by lipids, proteins, and DNA. The “components-targets” network constructed in this study reveals that the degrees of ESR1, PPAR-α, P2RX7, and PTGS2 are greater than those of other targets. Therefore, these targets may play a critical role in the anti-MI effect of VOA. As a ligand-activated transcription factor, ESR1 mainly mediates the biological effects of estrogen and its receptor modulators [44], and it also affects cell proliferation and differentiation in target tissues. ESR1 plays a vital role in maintaining the homeostasis of cardiomyocytes, regulating vasodilation, reducing cardiomyocyte apoptosis, and stimulating the formation of new blood vessels [45]. Meanwhile, PPAR-α is involved in the regulation of several bodily functions, including lipid metabolism, cell proliferation, and adhesion, and it is also implicated in pathways related to cytokines and inflammatory factors. The ligands of PPAR-α cure cardiovascular diseases and alleviate their complications. They also reduce the area of myocardial necrosis, improve ischemia and the function of posterior myocardial contraction, protect against acute myocardial injury, and enhance myocardial antiischemic ability [46]. As a member of the purinergic receptor family, P2RX7 is activated by extracellular ligands (such as ATP), and it participates in cell signal transduction, cytokine secretion, and mediation of cell growth, among other biological functions [47]. The activation of P2RX7 can cause microvascular dysfunction and local hypoxia [48]. As for PTGS2 (also known as COX-2), it is responsible for producing inflammatory prostaglandins [49, 50]. According to previous reports, COX-2 inhibitors have a protective effect against myocardial ischemic injury in adult rabbits [51].

Based on KEGG enrichment analysis, the AGE-RAGE, sphingolipid, VEGF, and cAMP signaling pathways are closely related to the anti-MI properties of VOA. AGEs can reduce blood vessel elasticity and NO content, resulting in damaged vascular endothelial cell function [52]. The combination of AGEs and receptor RAGE promotes the expression of a series of atherosclerosis-related genes such as vascular cell adhesion molecule-1, tissue factor, and monocyte chemoattractant protein-1 [53]. The sphingomyelin signaling pathway may also be implicated in the pathophysiological mechanism of ischemia-reperfusion injury [54]. Ginsenoside F11 has anti-MI properties, and the underlying mechanism of action may involve the regulation of multiple signaling pathways such as sphingomyelin metabolism, arachidonic acid metabolism, and linoleic acid metabolism [55]. MicroRNA-320a mediates doxorubicin myocardial injury through targeted inhibition of the VEGF signaling pathway. The inhibition of microRNA-320a expression can alleviate cardiac injury [56].

5. Conclusions

In conclusion, this study shows that VOA can protect against myocardial ischemia by regulating biological processes such as blood circulation, small-molecule metabolism, and cytokine production. The protective effect of VOA is associated with several targets, mainly COX-2, PPAR-α, and ESR1, that are involved in the AGE-RAGE, sphingolipid, VEGF, and cAMP signaling pathways. Considering that COX-2 is a key target in the VEGF signaling pathway and that PPAR-α is a key target in the cAMP signaling pathway, the anti-MI mechanism of VOA may involve both pathways. Moreover, ß-asarone and α-asarone may be the main components in VOA responsible for its protective effect against myocardial ischemia.

Data Availability

All datasets used to support the findings of this study are included within this study/supplementary materials.

Ethical Approval

The study on mice was approved by the Ethics Committee of the Experimental Animal Science and Technology Center of Jiangxi University of Traditional Chinese Medicine (no. JZLLSC2019-0139).

Disclosure

Zhen-zhong Zang and Li-mei Chen are the co-first authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

ZZZ and LMC designed the experiments and drafted, edited, and checked the article. YL and QD performed Western blot analysis. PX participated in the discussion and prepared the chart. QS performed statistical analyses. The corresponding authors YMG, MY, and HNL guided the formation of the entire article. All authors contributed to the article and approved the submitted version. ZZZ and LMC have contributed equally to this work and share first authorship.

Acknowledgments

This study was supported by Jiangxi Province Key Research and Development Project (S2019ZDYFB0029) and Jiangxi University of Traditional Chinese Medicine 1050 youth talent project (5142001007).

Supplementary Materials

Detailed search strategy. (Supplementary Materials)

References

  1. Z. Ke, G. Wang, L. Yang et al., “Crude terpene glycoside component from Radix paeoniae rubra protects against isoproterenol-induced myocardial ischemic injury via activation of the PI3K/AKT/mTOR signaling pathway,” Journal of Ethnopharmacology, vol. 206, pp. 160–169, 2017. View at: Publisher Site | Google Scholar
  2. C. Zhao, F. Meng, L. Geng et al., “Cardiac-protective effects and the possible mechanisms of alatamine during acute myocardial ischemia,” Canadian Journal of Physiology and Pharmacology, vol. 94, no. 4, pp. 433–440, 2016. View at: Publisher Site | Google Scholar
  3. J. D. Zhou, Z. Yang, Y. Fu, and Q. T. Zhao, “Research progress on the mechanism of traditional Chinese medicine intervention in myocardial ischemia,” Shandong Journal of Traditional Chinese Medicine, vol. 38, no. 8, pp. 799–801 + 808, 2019. View at: Google Scholar
  4. H. M. Sun, Effects of Acupuncture at Neiguan Point on Myocardial Protection in Rats with Myocardial Ischemia and Glutamate Metabolism Related Mechanisms, Lanzhou University, Lanzhou, China, 2018.
  5. B. H. Xu and L. Xu, “Advances in studying on Chinese medicine of anti-myocardial ischemia pharmacology,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 17, no. 15, pp. 265–269, 2011. View at: Google Scholar
  6. Z. Cheng, H. Shu, S. Zhang et al., “From folk taxonomy to species confirmation of Acorus (Acoraceae): evidences based on phylogenetic and metabolomic analyses,” Frontiers in Plant Science, vol. 11, p. 965, 2020. View at: Publisher Site | Google Scholar
  7. H. Shu, S. Zhang, Q. Y. Lei et al., “Ethnobotany of Acorus in China,” Acta Societatis Botanicorum Poloniae, vol. 87, no. 2, p. 3585, 2018. View at: Publisher Site | Google Scholar
  8. National Pharmacopoeia Commission, Pharmacopoeia of the People’s Republic of China (Part One), China Medical Science and Technology Press, Beijing, China, 2015.
  9. S. Y. Wu, C. Z. Yang, T. S. Cai, and W. Bai, “Textual research on materia medica of Acorus tatarinowii,” Journal of Chinese Medicinal Materials, vol. 39, no. 9, pp. 2150–2156, 2016. View at: Google Scholar
  10. H. F. Li, R. N. Shi, W. J. Han, H. Y. Wang, F. Ding, and Z. B. Huang, “Recent progress in pharmacological effects and related mechanisms of medicinal herb Acorus tatarinowii,” Lishizhen Medicine and Materia Medica Research, vol. 27, no. 11, pp. 2728–2730, 2016. View at: Google Scholar
  11. F. Cheung, “TCM: made in China,” Nature, vol. 480, no. 7378, pp. S82–S83, 2011. View at: Publisher Site | Google Scholar
  12. Y. X. Gong, Y. H. Tian, J. Nan, and W. B. Yu, “Complete plastome sequence of Acorus tatarinowii (Acoraceae), a traditional Chinese medicinal plant from Xishuangbanna, Yunnan, China,” MItochondrial DNA Part B, vol. 5, no. 1, pp. 226–228, 2020. View at: Publisher Site | Google Scholar
  13. R. N. Zhong, X. H. Wang, L. Wan, C. Y. Shen, and H. L. Yuan, “Study on preparation of volatile oil from Acorus tatarinowii self-nanoemulsion dropping pills and its protective effect on acute myocardial ischemia injury,” China Journal of Chinese Materia Medica, vol. 44, no. 7, pp. 1357–1362, 2019. View at: Google Scholar
  14. Q. D. Wu, Y. Q. Fang, Y. Z. Chen, Z. S. Kuang, S. Y. Wang, and Y. P. He, “Protective effects of volatile oil of Acorus tatarinowii schott and β-asarone on cardiovascular system,” Traditional Chinese Drug Research & Clinical Pharmacology, vol. 16, no. 4, pp. 244–247, 2005. View at: Google Scholar
  15. X. P. Dong and F. Deng, “Research progress on quality standards of Acorus,” Journal of Chengdu Unversity of Tarditional Chinese Medicine, vol. 45, no. 1, pp. 60–63, 2001. View at: Google Scholar
  16. X. L. Chen, D. J. Yuan, X. R. Wu, and Q. D. Wu, “Comparative study on quality of volatile oil of acori tatarinowii rhizoma from two habitats,” Journal of Chinese Medicinal Materials, vol. 38, no. 4, pp. 770–773, 2015. View at: Google Scholar
  17. Y. Xu, J. K. Miao, H. J. Liu et al., “Effect of α-asarone on lipopolysaccharide induced inflammatory responses in primary cultured microglial cells of rat,” The Chinese Journal of Clinical Pharmacology, vol. 33, no. 2, pp. 140–143, 2017. View at: Google Scholar
  18. H. Lu, J. Li, M. Li, T. Gong, and Z. Zhang, “Systemic delivery of alpha-asarone with Kolliphor HS 15 improves its safety and therapeutic effect on asthma,” Drug Delivery, vol. 22, no. 3, pp. 266–275, 2015. View at: Publisher Site | Google Scholar
  19. K. Wei and S. D. Li, “Observation on the curative effect of α-asarone injection,” Central Plains Medical Journal, vol. 27, no. 11, p. 62, 2000. View at: Google Scholar
  20. C. Shi and Y. Q. Fang, “Study on the effect of β-asarone on bronchial asthma,” LiShiZhen Medicine and Materia Medica Research, vol. 9, pp. 1873-1874, 2006. View at: Google Scholar
  21. L. Li, Y. Y. Zou, C. Shi et al., “Research on the asthma-reducing effect of asthma model in Guinea pigs treated with β-asarone through stomach-perfusion and spray administration,” Chinese Archives of Traditional Chinese Medicine, vol. 24, no. 12, pp. 2244-2245, 2006. View at: Google Scholar
  22. M. Y. Tang, J. Q. Lu, Y. Pang, H. Lin, and M. P. Yu, “Research progress of Acorus tatarinowii and its chemical constituents in prevention and treatment of cardiovascular disease,” Lishizhen Medicine and Materia Medica Research, vol. 31, no. 4, pp. 926–928, 2020. View at: Google Scholar
  23. Y. M. Cui, C. H. Li, C. Zeng et al., “Tongmai Yangxin pills anti-oxidative stress alleviates cisplatin-induced cardiotoxicity: network pharmacology analysis and experimental evidence,” Biomedicine & Pharmacotherapy, vol. 108, pp. 2018–1089, 2018. View at: Publisher Site | Google Scholar
  24. M. Hong, S. Li, N. Wang, H.-Y. Tan, F. Cheung, and Y. Feng, “A biomedical investigation of the hepatoprotective effect of Radix salviae miltiorrhizae and network pharmacology-based prediction of the active compounds and molecular targets,” International Journal of Molecular Sciences, vol. 18, no. 3, pp. 620–628, 2017. View at: Publisher Site | Google Scholar
  25. F. Bai, Y. Xu, J. Chen et al., “Free energy landscape for the binding process of Huperzine A to acetylcholinesterase,” Proceedings of the National Academy of Sciences, vol. 110, no. 11, pp. 4273–4278, 2013. View at: Publisher Site | Google Scholar
  26. S. Ohlson, “Designing transient binding drugs: a new concept for drug discovery,” Drug Discovery Today, vol. 13, no. 9-10, pp. 433–439, 2008. View at: Publisher Site | Google Scholar
  27. S. Li and B. Zhang, “Traditional Chinese medicine network pharmacology: theory, methodology and application,” Chinese Journal of Natural Medicines, vol. 11, no. 2, pp. 110–120, 2013. View at: Publisher Site | Google Scholar
  28. H. Li, L. Zhao, B. Zhang et al., “A network pharmacology approach to determine active compounds and action mechanisms of ge-gen-qin-lian decoction for treatment of type 2 diabetes,” Evid Based Complement Alternat Med, vol. 2014, Article ID 495840, 2014. View at: Publisher Site | Google Scholar
  29. S. Li, Z. Q. Zhang, L. J. Wu, X. G. Zhang, Y. Y. Wang, and Y. D. Li, “Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network,” IET Systems Biology, vol. 1, no. 1, pp. 51–60, 2007. View at: Publisher Site | Google Scholar
  30. Y. H. Fang, Y. J. Ying, Y. S. Zhu, and Z. G. Chen, “Effect of honeysuckle flower compound preparation in rats with acute myocardial oschemia induced by isoprenaline,” Chinese Journal of Clinical Rehabilitation, vol. 10, no. 7, pp. 61–63, 2006. View at: Google Scholar
  31. D. Zhang, L. Q. Jia, G. L. Yang, Y. Li, and F. Chen, “Study on the modeling method of acute and chronic myocardial ischemia model,” Journal of Practical Traditional Chinese Internal Medicine, vol. 32, no. 5, pp. 75–77, 2018. View at: Google Scholar
  32. Y. Tang, G. Ren, Q. Huang et al., “Analysis of the chemical constituents of volatile oil from Acorus calamus,” Jiangxi Journal of Traditional Chinese Medicine, vol. 45, no. 12, pp. 60–62, 2014. View at: Google Scholar
  33. J. M. Alves-Silva, M. Zuzarte, C. Marques, H. Girão, and L. Salgueiro, “Protective effects of phenylpropanoids and phenylpropanoid-rich essential oils on the cardiovascular system,” Mini Reviews in Medicinal Chemistry, vol. 19, no. 17, 2019. View at: Publisher Site | Google Scholar
  34. P. Hou, L. Yang, N. Liu, and L. Chen, “Effects of ephedrine, β-asarone and higenamine on calcium concentration and cell membrane calcium channels in rat ventricular myocytes,” Journal of China Medical University, vol. 42, no. 3, pp. 201–203, 2013. View at: Google Scholar
  35. R. Wang, M. S. Jin, J. H. Liu, H. Liu, and X. L. Wang, “Effect of beta-asarone on adriamycin-induced cardiomyocyte injury in suckling mouse,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 19, no. 16, pp. 202–205, 2013. View at: Google Scholar
  36. J. J. Wu, K. Y. Huang, H. Li et al., “β-asarone inhibits nuclear factor Kappa B expression,” Anatomy Research, vol. 34, no. 2, pp. 104–106, 2012. View at: Google Scholar
  37. Y. P. He, Y. Jiang, Y. S. He, S. Y. Wang, and F. Q. Yong, “Experimental study on the effect of β-octyl ether on the intracellular calcium concentration of ECV304 cells injured by ox-LDL,” Chinese Journal of Traditional Medical Science and Technology, vol. 17, no. 4, pp. 318-319, 2010. View at: Google Scholar
  38. Y. P. He, H. B. Wu, Y. Q. Fang, G. Wei, and S. F. Lin, “The dynamic study on the effect of β-asarone on platelet activation in rats with cerebral ischemia,” Study Journal of Traditional Chinese Medicine, vol. 23, no. 3, pp. 468-469, 2005. View at: Google Scholar
  39. R. Chellian, V. Pandy, and Z. Mohamed, “Pharmacology and toxicology of α- and β-Asarone: a review of preclinical evidence,” Phytomedicine, vol. 32, pp. 41–58, 2017. View at: Publisher Site | Google Scholar
  40. W.-K. Chan, L. Tan, K.-G. Chan, L.-H. Lee, and B.-H. Goh, “A sesquiterpene alcohol with multi-faceted pharmacological and biological activities,” Molecules, vol. 21, no. 5, p. 529, 2016. View at: Publisher Site | Google Scholar
  41. V. Juliana, G. Pedro, M. Fátima, and A. Manuel, “Assessment of the antioxidant and antiproliferative effects of sesquiterpenic compounds in in vitro Caco-2 cell models,” Food Chemistry, vol. 156, 2014. View at: Google Scholar
  42. J. Vinholes, A. Rudnitskaya, P. Gonçalves, F. Martel, M. A. Coimbra, and S. M. Rocha, “Hepatoprotection of sesquiterpenoids: a quantitative structure-activity relationship (QSAR) approach,” Food Chemistry, vol. 146, pp. 78–84, 2014. View at: Publisher Site | Google Scholar
  43. J. D. Nogueira Neto, R. M. de Freitas, J. Silva Oliveira, P. S. Santos, D. P. Sousa, and R. M. Freitas, “Antioxidant effects of nerolidol in mice hippocampus after open field test,” Neurochemical Research, vol. 38, no. 9, pp. 1861–1870, 2013. View at: Publisher Site | Google Scholar
  44. M. Liu, W. W. Xie, W. Zheng, D. Y. Yin, R. Luo, and F. J. Guo, “Targeted binding of estradiol with ESR1 promotes proliferation of human chondrocytes in vitro by inhibiting activation of ERK signaling pathway,” Journal of Southern Medical University, vol. 39, no. 2, pp. 134–143, 2019. View at: Google Scholar
  45. M. P. Sumi, S. A. Guru, R. Mir et al., “Clinical importance of estrogen receptor 1 (ESR1) gene polymorphisms and their expression patterns in coronary artery disease patients: a study from India,” Indian Journal of Clinical Biochemistry : IJCB, vol. 34, no. 2, 2019. View at: Publisher Site | Google Scholar
  46. L. Xu, Q. L. Tao, and J. Yuan, “Research progress on the effect of peroxisome proliferator-activated receptor α on cardiovascular diseases,” Chinese Journal of Difficult and Complicated Cases, vol. 14, no. 10, pp. 1081–1084, 2015. View at: Google Scholar
  47. Y. Zhang, J. J. Ding, and L. L. Wang, “The progress of relationship between P2X7 receptor and tumorigenesis,” Journal of Modern Oncology, vol. 26, no. 8, pp. 1307–1310, 2018. View at: Google Scholar
  48. R. I. Menzies, A. R. Howarth, R. J. Unwin, F. W. K. Tam, J. J. Mullins, and M. A. Bailey, “Inhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats,” Kidney International, vol. 88, no. 5, pp. 1079–1087, 2015. View at: Publisher Site | Google Scholar
  49. X. C. Wang, M. X. Chu, and H. Q. Chen, “Advances on prostaglandin-endoperoxide synthase 2 gene,” Chinese Bulletin of Life Sciences, vol. 16, no. 1, pp. 31–34, 2014. View at: Google Scholar
  50. H. C. Gao, X. Y. Yu, X. J. Li et al., “Expression of COX2 in myocardial fibriosis and its significantce,” Journal of Jilin University(Medicine Edition), vol. 34, no. 2, pp. 233–236, 2018. View at: Google Scholar
  51. B. Li, X. G. Yang, and L. J. Leng, “Effects of cyclooxygenase inhibitor on acute ischemic myocardium in rabbits,” Chinese Heart Journal, vol. 16, no. 2, pp. 113–115, 2004. View at: Google Scholar
  52. R. Bucala, K. J. Tracey, and A. Cerami, “Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes,” Journal of Clinical Investigation, vol. 87, no. 2, pp. 432–438, 1991. View at: Publisher Site | Google Scholar
  53. G. Su-Yen and M. E. Cooper, “The role of advanced glycation end products in progression and complications of diabetes,” Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 4, pp. 1143–1152, 2008. View at: Google Scholar
  54. W. Pan, The Role and Mechanism of Sphingolipids Signaling in Chronic Heart Failure, Central South University, Changsha, China, 2014.
  55. N. Q. Zhang, Study on theAnti-Myocardial Ischemia Effect and Pharmacokinetics of PF11 Pills, Jilin University, Changchun, China, 2018.
  56. M. Y. He, Z. W. Ying, Y. R. Zhao, H. P. Li, and J. G. Jiang, “MiR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway,” Molecular Cardiology of China, vol. 18, no. 5, pp. 2594–2599, 2018. View at: Google Scholar

Copyright © 2021 Zhen-Zhong Zang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views307
Downloads464
Citations

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.